Regeneron, Sanofi deal

Sanofi disclosed in its 1Q12 earnings that in February it terminated co-development of REGN475. Sanofi remains obligated to fund agreed-upon development costs through the end of 2012 and is eligible to receive a mid-single digit royalty. In 2009, the partners extended to 2017 the 2007 deal to discover, develop and commercialize human therapeutic antibodies using Regeneron's VelociSuite technologies. Details were not disclosed (see BioCentury, Dec. 3, 2007 & Nov. 16, 2009). ...